Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Ovarian Neoplasms 388Endometrial Neoplasms 221Uterine Cervical Neoplasms 217Breast Neoplasms 115Fallopian Tube Neoplasms 105Colorectal Neoplasms 91Carcinoma, Non-Small-Cell Lung 83Neoplasms 70Pancreatic Neoplasms 63Stomach Neoplasms 57Neoplasm Metastasis 54Prostatic Neoplasms 52Lung Neoplasms 49Melanoma 46Carcinoma, Ovarian Epithelial 44Triple Negative Breast Neoplasms 41Squamous Cell Carcinoma of Head and Neck 37Esophageal Neoplasms 37Carcinoma, Renal Cell 37Colonic Neoplasms 33Urinary Bladder Neoplasms 31Peritoneal Neoplasms 30Uterine Neoplasms 29Head and Neck Neoplasms 29Carcinoma, Hepatocellular 28Vulvar Neoplasms 27Small Cell Lung Carcinoma 25Carcinoma, Transitional Cell 25Uterine Cervical Dysplasia 22Sarcoma 19

Interventions

temsirolimus 1ixabepilone 1Taxes 1Sirolimus 1Paclitaxel 1Immunoglobulin G 1Epothilones 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Adenocarcinoma × Gynecologic × 90 days × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡